2 - aminoalkylamino-benzophenones-oximes and imines and the salts thereof



United States Patent 3,431,304 2 AMINOALKYLAMINO-BENZOPHENONES- OXIMES AND [MINES AND THE SALTS THEREOF Rodney Ian Fryer, North Caldwell, Earl Reeder, Nutley, and Leo Henryk Sternbach, Upper Montclair, N.J., assignors to Hoffman-La Roche Inc., Nutley, N.J., a corporation of New Jersey No Drawing. Filed Sept. 22, 1965, Ser. No. 489,381 US. Cl. 260-570 6 Claims Int. Cl. C07c 97/10, 131/00; A61k 27/00 ABSTRACT OF THE DISCLOSURE Z-(aminoalkylarnino) benzophenones, derivatives thereof and process for their preparation. Such compounds are conveniently, for example, prepared by hydrolysis of the corresponding benzodiazepinone. They are useful in reversing central nervous system depression in warm blooded animals. For this purpose these compounds are preferably prepared as their pharmaceutically acceptable acid addition salt derivatives.

The present invention relates to chemical compounds certain of which are novel and to processes for preparing same, said compounds having valuable therapeutic properties.

More particularly, the present invention relates to a process for treating psychiatric disorders caused by a depressed state which comprises administering to a host an ortho amino phenyl aryl ketone, oxime or imine, the amino nitrogen of which is substituted with a basic side chain. The present invention further relates to novel amino phenyl aryl ketones, imines and oxime derivatives thereof having a basic side chain attached to the aniline nitrogen and to processes for preparing same.

In one comprehensive aspect the invention relates to a method for reversing central nervous system depression which comprises administering to a warm blooded animal a non-toxic physiological amount of a member selected from the group consisting of compounds of the formula wherein n is a whole integer from 2 to 7; A is selected from the group consisting of oxygen, NH, NOI-I and N-lower alkyl; B is selected from the group consisting of phenyl, pyridyl, preferably, 2- or 4-pyridyl, and R -phenyl, preferably, 2-R -phenyl wherein R is selected from the group consisting of hydrogen, halogen, trifiuoromethyl, nitro, lower alkyl and lower alkoxy; R and R are selected from the group consisting of hydrogen, halogen, lower alkyl, trifiuorornethyl, nitro, amino and lower alkoxy; R is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl and R and R are selected from the group consisting of, individually, hydrogen and lower alkyl, and when taken together with the nitrogen atom, a mono-heterocyclic ring structure including at the most one further hetero atom selected from the group consisting of nitrogen and oxygen and at the most one further substituent on the hererocyclic ring nucleus and acid addition salts thereof with pharmaceutically acceptable acids. In a preferred aspect, R is hydrogen. In the most preferred aspect, R is hydrogen and R is joined to the phenyl ring at the 5-position thereof.

In administering a compound of the Formulae I, II,

3,431,304 Patented Mar. 4, 1969 ice III and IV to a warm blooded animal host, there is utilized from about 0.1 mg. to about mg. thereof per kilogram of body weight of the said animal host, preferably, from about .1 mg. to about 30 mg. thereof per kilogram of body weight of the said animal host, and most preferably, from about .2 mg. to about 10 mg. thereof per kilogram of body weight of the said animal host.

In another comprehensive aspect, the present invention relates to novel compounds of the formula wherein m is a whole integer from 1 to 5; A is selected from the group consisting of oxygen, NH, NOH and N- lower alkyl; B is selected from the group consisting of phenyl, pyridyl and R -phenyl wherein R is selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro, lower alkyl and lower alkoxy; R. is selected from the group consisting of hydrogen and lower alkyl; R and R are selected from the group consisting of hydrogen, halogen, lower alkyl, trifluoromethyl, nitro, amino and lower alkoxy; R is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl and R and R are selected from the group consisting of, individually, hydrogen and lower alkyl, and, when taken together with the nitrogen atom, a monohererocyclic ring structure including at the most one further hetero atom selected from the group consisting of nitrogen and oxygen and, at the most, one further substituent on the heterocyclic ring nucleus;

and acid addition salts thereof with pharmaceutically acceptable acids.

In a preferred aspect, all of the Rs in Formula II above are selected from the group consisting of hydrogen or methyl. In a still more preferred embodiment, all of the Rs are hydrogen. Advantageously, the sum of the carbon atoms contained in the substituents designated as R and the numerical value of the integer designated as m, is 5 or less. Thus, if m is 2, the R groups contain collectively a total of 3 or less carbon atoms, e.g. at least three of the R groups are hydrogen and the remainder are methyl.

Due to their particularly advantageous usefulness in a therapeutic sense as a class, an especially preferred group of novel compounds are those of the Formula II above wherein the R groups are all hydrogen, m is 1, one of R and R is lower alkyl and the other of R and R is hydrogen or lower alkyl, i.e. compounds of the formula wherein R, R R R A and B are as above and their acid addition salts with pharmaceutically acceptable acids. Most preferred among this grouping are compounds of Formula III above wherein R is hydrogen.

Another group of novel compounds included within the purview of the invention disclosed herein are those of the formula wherein R, R R R A and B are as above and their acid addition salts with pharmaceutically acceptable acids.

The expression lower alkyl as utilized herein unless otherwise specified is intended to connote a straight or branched chain hydrocarbon group having 1 to 7 carbon atoms in the chain, such as methyl, ethyl, propyl, isopropyl, butyl and the like. The term halogen as used herein represents all four halogens, namely, bromine, chlorine, iodine and fluorine, unless otherwise stated. The expression lower alkoxy as utilized herein designates a straight or branched chain, saturated hydrocarbonoxy group such as methoxy, ethoxy, isopropyloxy and the like. The expression lower alkenyl represents a straight or branched chain ethylenically unsaturated hydrocarbon group having 1 to 7 carbon atoms in the chain such as allyl and the like.

The grouping included in Formula II above wherein each of the R groups are hydrogen can represent a straight chain alkylene group such as, preferably, trimethylene, tetramethylene or pentamethylene. When one or more of the Rs are other than hydrogen, then the grouping t i t ave R .Rm

of Formula II above can represent an alkylene group having lower alkyl substituents thereon such as a l-methylpropylene group, a Z-methyl-propylene group, a l-methylbutylene group, a 3,3-dimethyl-propylene group and the like. As is noted above, the sum of the number of carbon atoms contained in all of the substituents identified as R in Formula II above and the value of the whole integer represented by m preferably does not exceed 5.

The symbols R and R have the following significance: R and R when taken individually, represent hydrogen or straight or branched chain hydrocarbon groups having from 1 to 7 carbon atoms in the chain such as methyl, ethyl, propyl, isopropyl, butyl and the like.

Thus, the

radical can represent amino, mono-lower alkyl amino, and di-(lower alkyl)amino; R and R when together, can comprise divalent groups which together with the nitrogen atom to which they are attached form a 5- or 6-membercd monoheterocyclic ring structure. Preferably, the last-mentioned ring structure is selected from the group consisting of piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl and substituted derivatives thereof. If the heterocyclic ring structure is substituted, the latter contains an additional nitrogen atom to which the subsituent atom or group is adjoined. Amon such substituents may be included branched or straight chain lower alkyl groups such as methyl, ethyl, isopropyl and the like, hydroxy lower alkyl groups, such as hydroxy ethyl and the like, I

lower alkenyloxy-lower alkyl groups such as vinyl-oxy alkyl and lower alkoXy-lower alkyl groups such as ethoxyethyl and the like. In a particular advantageous embodiment of this aspect of the present invention, one of R and R is lower alkyl and the other of R and R is hydrogen or lower alkyl. Especially preferred are those compounds wherein R and R are both lower alkyl.

As is evident from the above, the radical can represent a saturated 5- or 6-membered heterocyclic radical of the type identified below.

Piperidino (Lower alkyl)piperidino (Lower alkoxy)piperidino 2,3 or 4-piperidyl 2,3 or 4-(N-lower alkyl-piperidyl) Pyrrolidino (Lower alkyl)-pyrrolidino (Lower alkoxy)pyrrolidino 2- or 3-pyrrolidyl 2- or 3-(N-lower alkyl pyrrolidyl) Morpholino (Lower alkyl) piperazino (Hydroxy-lower alkyl)piperizino (Lower alkenyl-oxy-lower alkyl)pipera2ino (Lower alkoxy-lower alkyl)piperazino Piperazino Thus, when R and R combine to form a ring, the said heterocyclic ring structure so-formed is preferably saturated and contains 5- or 6-members in the ring. Thus, R and R when taken together, can represent, for example, a lower alkylene chain such as polymethylene chain of 4-5 carbon atoms, a lower alkyleneoxylower alkylene chain or a lower alkylene-aza-lower alkylene chain.

In addition to the compounds encompassed by Formulas I, II, III and IV above, there is also included within the purview of the present invention, the pharmaceutically acceptable acid addition salts of said compounds. The compounds of Formula I above (and, of course, the compounds of Formulas II, III and IV above encompassed thereby) form pharmaceutically acceptable acid addition salts with 1 or more mole equivalents of said acid depending upon the number of basic nitrogen atoms present. For example, they form salts with inorganic and organic acids such as hydrochloric acids, hydrobromic acid, citric acid, phosphoric acid, tartaric acid, salycilic acid, toluenesulphonic acid, ascorbic acid, nitric acid, succinic acid, formic acid and the like.

Compounds of Formulas I, II, III and IV above, as well as their pharmaceutically acceptable acid addition salts as is noted above are characterized by their anti-depressant action on the central nervous system and are useful, not only in the relief of symptomology associated with depression of the central nervous system, but are also useful in the prevention and reversal of central nervous system depression caused by exogenous chemical agents.

Ketones, oximes and imines of the formula wherein R R A and B are as above having been known heretofore. However, such type compounds were thought to be only useful in the preparation of other therapeutically useful compounds. The present applicants have unexpectedly found that compounds of Formula V above are valuable anti-depressant agents and this finding of heretofore unknown utility constitutes a part of the present invention.

The compounds of Formulas I, II, III and IV above can be prepared by a wide variety of reaction routes.

In one such reaction route, a compound of the formula wherein R R R R and B are as above.

Among the acid agents suitable for such a conversion of compounds of Formula VI above to the corresponding compounds of Formula I above wherein R is hydrogen may be included mineral acids, such as sulfuric acid, nitric acid, polyphosphoric acid, hydrohalic acids, e.g. hydrochloric acid and the like. In the preparation of compounds of Formulas I, II, III and IV above from the compounds of Formula VI above in the manner outlined hereinabove, temperature and pressure are not critical. Thus, the reaction can be effected at room temperature and atmospheric pressure or above or below room temperature. Advantageously, elevated temperatures are utilized. It is most preferred to run the reaction at about the reflux temperature of the reaction mixture.

Still another technique for preparing compounds of Formula I above involves reacting a compound of the formula R2 B VII wherein n is as above, whereby to prepare the corresponding compounds of the Formula I above wherein R and R are both hydrogen.

In a preferred embodiment, elevated temperatures are utilized when effecting the conversion of compounds of Formula VII above to compounds of Formula I above wherein R and R are both hydrogen, e.g. at an elevated temperature above about 75 C. Representative of compounds of Formula VIII above suitable for the purposes of this aspect of the present invention are, for example, 1,3-propane diamine, 1,3-(2-methyl propane)-diamine, 1,3-butane-diamine and the like. The compound of Formula VIII above utilized can be present in excessive amounts whereby it serves per se as the reaction medium. In an alternate procedure, any conveniently available non-re active organic solvent such as N,N-dimethylformamide, dimethyl sulfoxide, or an amine, a lower or higher alkanol such as pyridine, picoline, quinoline and the like can be used as the reaction medium.

Another preparative technique for preparing compounds of the Formula I above comprises reacting a compound of the formula wherein R, R R A and B are as above, with a compound of the formula halo- -halo wherein n is as above, and treating the so-formed compound of the formula N-C Han-halo wherein n, R R R A and B are as above, with a member selected from the group consisting of ammonia, a primary amine of the formula RNH wherein R is as above and a secondary amine of the formula wherein R and R are as above in the presence of an alkali such as sodium hydroxide and the like and any suitable inert organic solvent. When ammonia is utilized, compounds of the Formula I above result wherein R and R are both hydrogen. When a primary amine is utilized, compounds of Formula I above result wherein one of R and R is hydrogen and the other of R and R is lower alkyl. When a secondary amine is utilized, compounds of Formula I above result wherein R and R are both lower alkyl, or when taken together, a mono-heterocyclic ring structure of the type more fully described hereinabove.

The N-mono lower alkyl derivatives of the compounds of Formula I above wherein R and R are both hydrogen can be prepared by refluxing the primary amine with ethyl formate to yield the N-formyl derivative thereof. The so prepared N-formyl compound is then refluxed with sodium hydride and for example methyl iodide in diethylene glycol dimethylether yielding compounds of the formula R1 llh lower alkyl NGnH2n N form yl r R2 B wherein n, R R R A and B are as above, which upon hydrolysis by refluxing in hydrochloric acid, yields compounds of Formula I above wherein one of R and R is hydrogen and the other of R and R is lower alkyl.

The N-di-lower alkyl derivatives of compounds of Formula I above wherein R and R are both lower alkyl are obtained by alkylation of the corresponding primary amines of Formula I above with a mixture of an appropriate aqueous aldehyde and an appropriate lower alkanoic acid. For example, compounds of Formula I above wherein R and R are both methyl can be prepared from the corresponding primary amines of Formula I above, i.e. wherein R and R are both hydrogen, by methylation of the last-mentioned primary amine with a mixture of aqueous formaldehyde and formic acid.

Compounds of formulae I, II, II and IV above wherein A is an NOH group (an oxime) can be prepared from the corresponding compound of Formulae I, II, III and IV above wherein A is oxygen (a ketone) by reacting the last-mentioned compound with hydroxyl-amine.

This reaction is preferably effected in the presence of any suitable inert organic solvent such as pyridine or ethanol.

Compounds of Formulas I, II, III and IV above wherein A is an NH group or an N-lower alkyl group can be prepared from the corresponding compound of Formulas I, II, III and IV above wherein A is oxygen (a ketone) by reacting such compounds with ammonia or a primary amine under pressure. The reaction with ammonia results in compounds of Formulas I, II, III and IV above wherein A is an NH group. The reaction of compounds of Formulas I, II, III and IV above with a primary amine results in the corresponding compounds wherein A is an Nlower alkyl group.

Compounds corresponding to Formulas I through IV above wherein R is hydrogen can be modified so that R is other than hydrogen by a variety of methods. For example, compounds of Formulas I through IV above wherein R is other than hydrogen can be obtained by reacting corresponding compounds wherein R is hydrogen with diazoalkanes, e.g. diazomethane, di-lower alkyl sulfates, e.g. dimethyl sulfate, lower alkyl halides, e.g. methyl iodide and lower alkenyl halides, e.g. allyl bromide in a medium such as ether, benzene, an alcohol (ethanol), dimethyl-formamide, dioxane and the like. Suitably, the reaction is effected utilizing sodium methoxide, sodium hydride and the like to form the sodio derivative of the 2 position nitrogen atom of compounds of Formulae I through IV above and reacting the so-called sodio derivative with an equivalent amount or an excess of the appropriate alkylating agent or alkenylating agent.

Another method of preparing compounds of Formula IV above involves reacting a quaternary compound containing a cation of the formula B lower alkyl wherein R, R R R and B are as above, with a base. This procedure is especially advantageous in preparing compounds of the Formula IV above wherein R is other than hydrogen.

The last-mentioned reaction is preferably effected in an aqueous medium which may include an inert organic solvent miscible with water such as methanol, ethanol and the like. The base utilized may be represented by alkali metal hydroxides, e.g. sodium hydroxide, alkaline earth metal hydroxides, e.g. calcium hydroxide and the like. Any suitable temperature may be employed during this reaction step. However, it is preferred to operate at temperatures below room temperature.

As is noted above, the compounds of Formula I above as well as their pharmaceutically acceptable acid addition salts are characterized by their ability to reverse central nervous system depression and hence are useful as antidepressants. They can be administered internally, for example, parenterally or enterally in conventional pharmaceutical dosage forms with dosage adjusted to fit the exigencies of a particular therapeutic situation. The pharmaceutical dosage forms can be prepared by incorporating the active ingredient in liquid or solid vehicles to form elixirs, tablets, capsules, suspensions, suppositories and the like.

Compounds of Formula I above can also the formed by reacting a tosyl group-containing aniline derivative of the formula wherein A, B, R, and R are as above, with a compound of the formula wherein n, A, B, R R R and R are as above, and subsequently splitting off the tosyl group. An efficacious way of removing the tosyl group whereby to prepare the corresponding compound of Formula X above is heating a compound of Formula X above in the presence of a suitable proton-donating acid agent such as sulfuric acid and the like.

While a tosyl group is illustrated hereinabove as the leaving group in the compounds of Formulas IX and X above, it is of course to be understood that any equivalent leaving group such as another aryl sulfonyl group, e.g. benzene sulfonyl and the like or an acyl moiety such as 'acetyl and the like can be present in the compounds of the Formulas IX and X above in place of the tosyl group. Preferably, the leaving group is selected from the group consisting of acyl, benzene sulfonyl and derivatives thereof. However, all that is required of the leaving group is that it function efiicaciously in this process aspect, that is, that it be a suitable leaving group for the purposes of the present invention.

When preparing compounds of the formula wherein B, 11, R R R R and R are as above, via the reaction of compounds of Formula I above, wherein A is oxygen with a primary amine under pressure in the manner outlined hereinabove, compounds of the formula wherein R R R R R and n are as above, also result.

Compounds of Formula XI above can be treated with a strong acid to effect conversion thereof to compounds of the formula which in turn can be transformed into compounds having an oxime group or an imine group, respectively, via the reaction thereof with hydroxylamine and ammonia under pressure as described above.

Thus, there is further included within the purview of the present invention compounds of the formula III-lower alkyl 1 H wherein R R R R R and A are as above. Compounds of Formula XII are anti-depressants.

The following examples are illustrative, but not limitative of the present invention. All temperatures stated therein are in degrees centigrade.

Example 1 To 161 g. (0.360 m.) of 7-chloro-1-(3-dimethylamino prop-yl)-5-(2-fiuorophenyl) 1,3 dihydro-2H-l,4-benzodiazepin-Z-one dihydrochloride, there was added 900 ml. of ethanol, and 900 ml. of 3 N HCl. The solution was then heated under reflux for 8 hours. Most of the ethanol was removed under reduced pressure and the remaining solution was made basic PH 9; Hydrion papers) with concentrated ammonium hydroxide, keeping the solution at approximately room temperature by the addition of ice. The reaction mixture was extracted with methylene chloride (2X 300 ml.); the organic extracts were combined, washed with 200 ml. of brine and then 'dried over anhydrous sodium sulfate. The so washed and dried exracts were evaporated to dryness after the addition of 100 ml. of benzene. 127 g. of the oil thus obtained was dissolved in 200* ml. of petroleum ether, and filtered (without suction) through a column containing 400 g. of Grade I neutral alumina. Elution with 1300' ml. of petroleum ether gave a first fraction which upon evaporation yielded 5-chloro-2-(B-dimethylaminopropyl)-amino- 2-fiuorobenzophenone as an oil. The oil so-obtained was dissolved in 160 ml. of methanol and 40 ml. of 8.46 N methanolic HCl excess) was added. To the adduct, there was slowly added 800 ml. of ether, and the resultant solution was cooled overnight. The product was filtered, washed with ether and dried overnight at 55 to give 5-chloro-2(3-dimethylaminopropyl)-amin0 2' fluorobenzophenone hydrochloride as yellow rods having a melting point of 172174.

Example 2 A solution of 23.2 g. ("86 mmole) of 7-chloro-2,3-dihydro-l-methyl-S-phenyl-1H-1,4-benzodiazepine in 250 ml. of benzene and 100 mmole of dimethylsulfate was refluxed overnight. The solvent was removed in vacuo and the residue recrystallized from methylene chloride- 10 ether giving 7-chloro-2,3-dihydro-1,4-dimethyl-5-phenyl- 1H-1,4-benzodi azepin-4-ium methyl sulfate as orange prisms, M.P. 118-126".

A solution of 30.6 g. (78 mmole) of 7-chloro-2,3-dihydro 1,4 dimethyl-S-phenyl-IH-1,4-benzodiazepin-4- ium methyl sulfate in ml. of water was stirred at 0. An equimolar amount of sodium hydroxide (78 mmole) in 50 ml. of water chilled to 0 was added dropwise to the aqueous medium over a period of 30 minutes. After the addition was about half completed, 50 m1. of ether was added to dissolve the free base formed. The reaction mixture was extracted with ether, dried over magnesium sulfate and concentrated in vacuo giving -chloro-2-(2- methylaminoethylmethylamino)-benzophenone. The base was dissolved in ether and the ethereal solution was treated with hydrogen bromide yielding 5-chloro-2-(2-methylaminoethylmethylamino)benzophenone dihydrobromide, melting point 150-160". Recrystallization from acetone gave the product as yellow prisms, M.P. unchanged. Additional recrystallizations from isopropanolether gave yellow prisms, melting point -150 of the monohydrobromide.

Example 3 A solution of 10 g. of (31.7 mmole) of 7-bromo-5-(4- pyridyl)-3H-1,4-benzodiazepin-2(1H)-one in ml. of freshly distilled dimethylformamide under dry nitrogen was stirred for 4 hours at room temperature with 1.95 g. 50 mmole) of sodamide. A dried cholorform solution of 1-ch1oro-3-(dimethylamino)propane (excess) was added and the reaction mixture stirred overnight. The reaction mixture was diluted with 300 ml. of water and extracted with chloroform. The chloroform extract was washed three times with water, dried over magnesium sulfate and concentrated in vacuo to a dark oil. The oil was washed five times with 100 ml. portions of hexane and the insoluble solid extracted continuously with hexane over a period of 20 hours. The hexane solutions were combined and concentrated to about 250 ml. Upon standing overnight, a precipitate formed which was separated by filtration. Removal of the hexane gave an oil. Crystallization of the oil gave colorless prisms, melting point 92-97 from ether-hexane. Two recrystallizations from ethercyclohexane gave colorless prisms of 7-bromo-1-(dimethylaminopropyl) 5-(4-pyridyl) 3H-1,4-benzodiazepin- 2(1H)-one, melting point 97.5-99".

A solution of 1.0 g. (2.5 mmole) of 7-bromo-1- (dimethylaminopropyl) 5-(4-pyridyl) 3H-1,4-benzodiazepin-2(1H)-one in 35 ml. of a 1:1 mixture of 6 N hydrochloric acid and ethanol was refluxed 7 hours. The reaction mixture was made basic with 3 -N sodium hydroxide and extracted four times with ether. The combined ether extracts were dried over magnesium sulfate and concentrated in vacuo to give 4-[5-bromo-2-(3- dimethylaminopropylamino)benzoyl]pyridine. An ethanolic solution of the base was treated with maleic acid and the salt recrystallized from ethanol-ether giving 4- [5 bromo 2 (3 dimethylaminopropylamino)benzoyl]pyridine maleate as yellow prisms, melting point 148151. Recrystallizations from ethanol'ether raised the melting point of the salt to 151-152.

Example 4 A solution of 36.9 g. (0.1 mole) of 7-chloro-1-(2- diethylaminoethyl) S-phenyl 3'I-I-1,'4-henzodiazepin-2 (1H)-one in 200 ml. of ethanol and 200 ml. of 3 N hydrochloric acid was stirred at reflux for 8 hours. The ethanol was removed in vacuo and the residue poured into an excess of iced ammonium hydroxide. The basic mixture was extracted with methylene chloride. The methylene chloride extract was dried over magnesium sulfate and concentrated in vacuo to give 2[-(2-di-ethylaminoethyl)arnino]-5-chlorobenzophenone. An ethereal solution of this base was treated with hydrogen chloride giving after recrystallization from isopropanol, 2[(2- diethylaminoethyl) amino] --chlorobenzophenone hydrochloride hemihydrate as yellow prisms, melting point 197199.

Example 5 A solution of 17 g. of 7-chloro-1-(Z-diethylaminoethyl) 5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-Z-one dihydrochloride in a mixture of 200 ml. of ethanol and 200 ml. of 3 N hydrochloric acid was heated under refiux for 18 hours. Ethanol was removed under reduced pressure and the residue made basic with ammonium hydroxide. The product was extracted into ether (2 100 ml.). The ether extracts were combined, washed with water, dried and evaporated leaving a yellow oil. The yellow oil thus obtained was dissolved in hexane and chromatographed over activated neutral alumina. The petroleum ether (B.P. 3060) fraction from the column which contained 5-chloro-2-(Z-diethylaminoethyl)amino- 2'-fluorobenzophenone was concentrated. The concentrate was dissolved in ether which was then saturated with dry hydrogen chloride. S-chloro-Z-(Z-diethylaminoethyl)amino-2-fluorobenzophenone hydrochloride precipitated as a yellow crystalline salt of melting point 134-143 and was separated by filtration.

Example 6 A solution of 17 grams of 7-chloro-1-(3-diethylaminopropyl) 5-(2-fluorophenyl) 1,3-dihydro-2H-1,4-benz0- diazepine-Z-one dihydrochloride in a mixture of 200 ml. of ethanol and 200 ml. of 3 N hydrochloric acid was heated under reflux for 18 hours. Ethanol was removed under reduced pressure and the residue made basic with ammonium hydroxide. The basic medium was extracted with ether (2 100 ml.). The ether extracts were combined, washed with water, dried and evaporated leaving an oil. The oil so obtained was dissolved in hexane. The

hexane solution was put on a column of activated neutral alumina and chromatographed with petroleum ether (BJI). 30-60). The petroleum ether fraction which contained 5-chloro-2- 3-diethylaminopropylamino -2-flu0robenzophenone was concentrated. The concentrate was added to an ether-acetone mixture which was then saturated with dry hydrogen chloride yielding 5-chloro-2-(3- diethylamino-propylamino) 2'-fluorobenzophenone hydrochloride as bright yellow prisms, melting point 114117.

Example 7 A solution of 17 grams of 7-bromo-1,3-dihydro-1-(3- dimethylaminopropyl) 5-(2-pyridyl)-2H-1,4-benzodiazepine-2-one dihydrochloride in a mixture of 200 ml. of ethanol and 20 ml. of 3 N-hydrochloric acid was heated under reflux for 18 hours. Ethanol was removed under reduced pressure and the residue made basic with ammonium hydroxide. The basic medium was extracted with ether (2 100 ml.). The ether extracts were combined, washed with water, dried and evaporated leaving an oil. Chromatography of the crude product over neutral activated alumina gave upon evaporation of the ethyl acetate fraction from the column 2-[5-br0mo-2-(3- dimethylaminopropylamino)-benzoyl]pyridine as a yellow oil. The oil was dissolved in a small amount of ethanol and dry hydrogen chloride was bubbled into the solution. The addition of ether caused 2-[5-bromo-2-(3- dimethylaminopropylamino) benzoyllpyridine dihydrochloride hemihydrate to percipitate as orange rods of melting point l77185 (with decomposition).

Example 8 17 grams of 7-chloro-1,3-dihydro-l-(3-dimethylaminopropyl)-5-pheny1-2H-1,4-benZodiaZepin-2-one in a mixtracts were combined, washed with water, dried and evaporated leaving an oil. The oil thus obtained was dissolved in hexane and chromatographed over active neutral alumina. Evaporation of the ethyl acetate fraction from the column yielded 5-chloro-2-(3-dimethylaminopropylamino)benzophenone as an oil. The free base thus obtained was dissolved in isopropanol. After passing dry hydrogen chloride into the isopropanol solution and adding ether, 5 chloro 2 (3 dimethylaminopropylamino) benzophenone hydrochloride precipitated. Recrystallization from methanol, ether mixture gave the salt as yellow prisms of melting point 157-163 Example 9 A solution of 5.5 g. of 7-chloro-5(2-fluorophenyl)-l,3- dihydro 1 (3-piperazinopropyl)-2H-1,4-benzodiazepin- 2-one in a mixture of 50 ml. of ethanol and 50 ml. of 3 N hydrochloric acid was refluxed for 5 hours. The ethanol was removed under reduced pressure and the residue made alkaline with ammonium hydroxide. The resultant oil was extracted with dichloromethane, washed with brine, dried over anhydrous sodium sulfate, filtered and concentrated to small volume. The so-concentrated dichloromethane solution was put on a column of Woelm Grade I neutral alumina and chromatographed with ethyl acetate to give a viscous, yellow oil. The oil was treated with a solution of maleic acid in methanol and let stand overnight. Filtration yielded bright yellow crystals of 5 chloro 2 (3-piperazinopropylamino)-2- fluorobenzophenone dimaleate melting point 157-159".

Example 10 A solution of 6 g. of 7-chloro-5-(2-fluorophenyl)-1,3- dihydro 1 [3 (methylpiperazino)propyl] 2H 1,4- benzodiazepin-Z-one in a mixture of 50 ml. of ethanol and 50 ml. of 3 N hydrochloric acid was refluxed for 4 hours. Ethanol was removed under reduced pressure and the residue made alkaline with ammonium hydroxide. Extraction with dichloromethane, followed by washing with brine, drying over anhydrous sodium sulfate, filtration, concentration of the dichloromethane extract to a small volume and chromatography over Woelm neutral alumina with ethyl acetate gave a yellow oil. The resultant oil was dissolved in methanol and treated with a methanol solution of maleic acid. Filtration gave a yellow solid. Recrystallization from ethanol gave brilliant yellow prisms of S-chloro-Z-[3-(4-methylpiperazino)propy-lamino]-2'-fluorobenzophenonc dimaleate melting point 185- 188".

Example 11 A solution of 3.5 grams of 7-chloro-5-(2-fluorophenyl) 1,3 dihydro 1 {3 [4 (2 hydroxyethyl)piperazine]propyl}-2H-1,4-benzodiazepin-2-one in a mixture of 50 ml. of ethanol and 50 ml. of 3 N hydrochloric acid was refluxed for 6 hours. Ethanol was removed under reduced pressure and the residue made alkaline with ammonium hydroxide. The so-formed alkaline medium was extracted with dichloromethane. The dichloromethane extract was washed with brine (3X 100 ml.) and dried over anhydrous sodium sulphate. Concentration of the filtrate to a small volume, chromatography using 35 grams of neutral alumina and elution with ethyl ether gave 5 chloro 2 {3 [4-(2-hydroxy-ethyl)piperazino] propylamino}-2'-fluorobenzophenone as a yellow oil. The yellow oil was treated with a methanol solution of 2 grams of maleic acid. Filtration gave a yellow solid which after recrystallization from acetone gave small yellow needles of 5-chloro-2-{3-[4-(Z-hydroxyethyl)piperazino] propyl-amino}-2-fluorobenzophenone dimaleate as yellow needles, melting point 166167.

Example 12 A solution of. 6 grams of 7-chloro-5-(2-fluorophenyl)- 1,3 dihydro 1 {3-[4-(2-vinyloxyethyl)piperazino1propyl}-2H-1,4-benzodiazepin-2-one in a mixture of ml.

13 of 3 N hydrochloric acid and 75 ml. of ethanol was refluxed for 9 hours. The ethanol was removed under reduced pressure and the residue was made alkaline with ammonium hydroxide. The alkaline medium was extracted with dichloromethane. The dichloromethane extract was washed With brine (3x 150 ml.) dried over anhydrous sodium sulphate, filtered and the filtrate concentrated to a small volume. The so-concentrated dichloromethane solution Was put on a column of neutral alumina and chromatographed with a 50-50 (v./v.) mixture of ethyl ether-ethyl acetate yielding -chloro-2-{3-[4-(2- vinyloxyethyl)piperazino]propylamino}2 fluorobenzophenone as a yellow oil. The yellow oil was treated with a methanolic solution of maleic acid. After allowing the resultant solution to stand overnight, the solid was filtered and recrystallized from acetone to give 5-chloro-2-{3-[4- (2 vinyloxyethyl)piperazino]propylamino} 2 fluorobenzophenone dimaleate as bright yellow prisms of melting point 140142.

Example 13 A solution of 4.8 grams of 7-chloro-1-{3-[4-(ethoxyethyl) 1piperazino]propyl} 5 (2 fluorophenyl)- 1,3-dihydro-2H-1,4-benzodiazepin-2-one trimaleate in 85 ml. of 3 N hydrochloric acid and 80 ml. of ethanol was refluxed for ten hours. The ethanol was removed under reduced pressure and the residue made alkaline with ammonium hydroxide. The so-formed alkaline medium Was extracted with dichloromethane. The dichloromethane extract was washed with brine, dried over anhydrous sodium sulphate, filtered and the filtrate concentrated to a small volume. The so-concentrated dichloromethane solution was put on a column of neutral alumina and chromatographed with ethyl acetate to give 5-chloro-2- {3 [4 (2 ethoxyethyl)piperizino]propylamino}-2- fluorobenzophenone as a yellow oil. Treatment of the yellow oil with a solution of maleic acid in methanol gave, after allowing the resultant solution to stand overnight, a yellow solid. Recrystallization of the salt from acetone yielded yellow prisms of 5-ch-loro-2-{3-[4-(2- ethoxyethyl)piperazinoJpropylamino} 2 fluorobenzophenone dimaleate, melting point 153-155 Example 14 A mixture of 7.3 g. (0.02 mole) of 7-chloro-1-(3- chloropropyl) 5 (2 fluorophenyl) 1,3 dihydro- 2H-1,4-benzodiazepin-2-one, 3.0 g. (0.02 mole) of sodium iodide, 7 g. (0.08 mole) of morpholine and 75 ml. of methylethyl ketone was refluxed for 22 hours. Solvents were removed under reduced pressure and the residue was partitioned between water and dichloromethane. The dichloromethane extract was washed with brine and the product extracted into 3 N hydrochloric acid. The acid extracts were combined, made basic with ammonium hydroxide and the product re-extracted with dichloromethane. The last-mentioned dichloromethane extracts were washed with brine, dried over sodium sulfate and concentrated to give a yellow oil. The oil was treated with a solution of maleic acid in methanol. The white solid which formed was recrystallized from methanol yielding colorless platelets of 7-chloro-5-(2-fluorophenyl)-l,3-dihydro 1 (3-morpholinopropyl)-2H-1,4-benzodiazepin- 2-one monomaleate melting point 183-185 Example 15 A solution of 5.9 grams of 7 chloro 5 (2 fluorophenyl) 1,3 dihydro 1 (3 morpholinopropyl)- 2H 1,4 benzodiazepin 2 one in a mixture of 70 ml. of 3 N hydrochloric acid and 70 ml. of ethanol was refluxed for 9 hours. The ethanol was removed under reduced pressure and the residue made alkaline with ammonium hydroxide. The so-formed alkaline medium was extracted with dichloromethane. The dichloromethane extract was washed with brine, dried over anhydrous sodium sulfate, filtered and the filtrate concentrated to a small volume. The so-concentrated dichloromethane solution was put on a column of neutral alumina and chromatographed with ethyl ether. Concentration of the ethyl ether gave 5 chloro 2 (3 morpholinopropyh amino) 2 fluorobenzophenone as an. oil. The so-obtained oil was dissolved in methanol and the resultant solution saturated with hydrogen chloride. The yellow solid which formed was recrystallized from methanolether and yielded 5 chloro 2 (3 morpholinopropylamino) 2' fluorobenzophenone hydrochloride as yellow needles of melting point 148450".

Example 16 A solution of 1.3 grams of 1 (2 dimethylaminoethyl) 5 phenyl 7 trifiuoromethyl 3H 1,4- benzodiazepin 2(1H) one dihydrochloride in 50 ml. of ethanol and 40 ml. of 3 N hydrochloric acid was refluxed for 8 hours. The ethanol was removed under reduced pressure and the residue made alkaline with ammonium hydroxide. The so-formed alkaline medium was extracted with dichloromethane. The dichloromethane extract was washed with brine, dried over anhydrous sodium sulphate, filtered and concentrated to a small volume. The so-concentrated dichloromethane solution was put on a column of neutral alumina and chromatographed with ethyl acetate. Concentration of the ethyl acetate gave 2 (2 dimethylaminoethylamino) 5- trifluoromethylbenzophenone as an oil. The oil was dissolved in ethanol, which was saturated with hydrogen chloride. Upon treatment with ether, a yellow solid was obtained which upon recrystallization from ethanol-ether gave 5 trifiuoromethyl 2 (2 dimethylaminoethylamino)benzophenone hydrochloride as yellow needles, melting point 203205.

Example 17 To a stirred mixture of 900 ml. of pyridine and 200 ml. of 1,3 propanediamine were added 104 g. of 2- chloro 5 nitrobenzophenone. The reaction mixture was refluxed for 5 hours and then concentrated in vacuo to dryness. The residue was shaken with a mixture of methylene chloride and water. The organic layer was separated, dried and concentrated in vacuo to dryness. The residue was dissolved in 1 1. of 1.5 N hydrochloric acid, stirred and refluxed for 2 hours and then left at room temperature for 18 hours. The crystalline reaction prod uct which formed was separated by filtration and recrystallized from methanol. After recrystallization from a mixture of methanol and ether, 2 (3 aminopropylamino) 5 nitrobenzophenone hydrochloride was obtained as yellow needles melting at 239240.

By treating the hydrochloride with sodium hydroxide, 2 (3 aminopropylamino) 5 nitrobenzophenone was obtained. Upon recrystallization of the last-mentioned basge from ether, there appeared yellow needles melting at 7-98.

Example 18 A solution of 3.6 g. of l (3 dimethylaminopropyl)- 1,3 dihydro 7 nitro 5 phenyl 2H 1,4 benzodiazepin 2 one hydrochloride in 50 ml. of a 50% mixture of ethanol and 3 N hydrochloric acid was heated on the steambath for 7 hours. The reaction mixture was diluted with ice water, made alkaline with dilute sodium hydroxide and extracted with methylene chloride. The organic layer was dried and concentrated in vacuo to dryness. The residue was crystallized and recrystallized from other yielding 2 (3 dimethylaminopropylamino)- 5 nitrobenzophenone as yellow prisms, melting point 105406".

2 (3 dimethylaminopropylamino) 5 nitrobenzophenone was dissolved in an excess of methanolic hydrogen chloride. The solution was concentrated in vacuo to dryness. The residue was crystallized from a mixture ofmethanol, isopropanol and ether. After recrystallizatron from the same solvent mixture, 2 (3 dimethylaminopropylamino) 5 nitrobenzophenone hydrochloride was obtained as yellow needles melting at l81l82.

Example 19 To a solution of 9.1 g. of 2 (3 aminopropylamino)- 5 nitrobenzophenone in 50 ml. of formic acid was added 50 ml. of 40% aqueous formaldehyde. The mixture was heated on a steambath for 1.5 hours and then refluxed for 18 hours. The reaction mixture was poured onto ice, made alkaline with dilute sodium hydroxide and extracted with ether. The ether extract was dried and concentrated in vacuo to dryness. The residue was dissolved in ether and extracted with dilute hydrochloric acid. The aqueous acid layer was separated, made alkaline with dilute sodium hydroxide and extracted with ether. The last-mentioned ether extract was dried and concentrated in vacuo to dryness. The residue was dissolved in an excess methanolic hydrogen chloride and concentrated in vacuo to dryness. The salt was crystallized from a mixture of methanol, isopropanol and ether yielding 2 (3 dimethylaminopropylamino) 5 nitrobenzophenone hydrochloride melting at 180181.

Example 20 A mixture of 50 g. of 7 bromo 1 (3 dimethylaminopropyl) 1,3 dihydro 5 phenyl 2H 1,4- benzodiazepin 2 one in 200 ml. of 3 N hydrochloric acid was heated on a steambath for 4 hours. The reaction mixture was left at room temperature for 18 hours, diluted with water and extracted with ether. The aqueous acid layer was separated, made alkaline with dilute soduim hydroxide. It was thereafter extracted with ether. The ether layer containing 5 bromo 2 (3 dimethylaminopropylamino)benzophenone was separated, dried and concentrated in vacuo to dryness. The residue was dissolved in 100 ml. of an excess of an ethanol, solution of maleic acid and the mixture was heated until complete solution Was obtained. The solution was concentrated in vacuo to dryness. The residue was crystallized and recrystallized from a mixture of methylene chloride and ether yielding 5 bromo 2 (3 dimethylaminopropylamino)benzophenone maleate as yellow needles melting at 110111.

Example 21 A solution of 0.013 m. of 5-chloro-2-paratoluenesulfonamido-benzophenone in 25 m1. of N,N-dimethylformamide was treated with a 3.2 ml. of a solution of sodium methoxide in methanol [(containing 4.87 meq./ml.); 0.156 m.]. The mixture was stirred at room temperature for minutes. A solution of 0.325 m. of dimethylaminopropyl chloride in 25 ml. of toluene was then added and the reaction mixture stirred at for eighteen hours. The reaction mixture was next concentrated to an oil, dissolved in ether (200 ml.) and then washed with water (3 x100 ml.). The ether solution was extracted with 6 N hydrochloric acid (3X50 ml.). The acid extracts were combined, washed with ether (100 ml.) made basic with ammonia and the resultant medium then extracted with ether (3x100 ml.). The ether extracts were combined, washed with water, dried over anhydrous sodium sulfate and concentrated whereupon 5-chloro-2[N-(3-dimethylaminopropyl) p toluenesulfonamidO]benzophenone crystallized. Upon recrystallization from a mixture of ether/petroleum ether, the product appeared as white prisms melting at 103-106".

Example 22 To 20 ml. of 70% (v./v.) sulfuric acid maintained at 105 was added 1.0 g. of 5-chloro-2-[N-(3-dimethylaminopropyl -p-toluene-sulfonamido] benzophenone. The resultant solution was stirred, heated to 145 and then maintained at that temperature for 5 minutes. The solution was then poured over ice, made basic with concentrated ammonium hydroxide and extracted with ether (3X50 ml.). The ether extracts were combined, washed with water, dried over anhydrous sodium sulfate and" concentrated leaving 5 chloro 2-(3-dimethylaminopropylamino)benzophenone in the concentrate. An excess of a solution of dry hydrogen chloride in isopropanol was added to the so-formed concentrate yielding 5-chloro-2- (3-dimethylaminopropylamino) benzophenone hydrochloride. The salt was precipitated by the addition of ether as yellow prisms melting at 157-163.

Example 23 A solution of 17.4 g. (0.05 mole) of 7-chloro-1-(3- chloropropyl) 1,,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one in ml. of ethanol and 100ml. of 3 N hydrochloric acid was refluxed overnight. The so-refiuxed acidic solution was washed with ether, neutralized with aqueous sodium hydroxide and extracted with ether. The ethereal extract was dried and the solvent removed leaving a yellow oil. The yellow oil was chromatographed over alumina (Woelm neutral, activity 1). Elution with petrol and subsequent removal of the solvent gave 2-(3-chloropro pylamino)-5-chlorobenzophenone, as yellow prisms melting point 60-62.

Example 24 A mixture of 9.0 g. (29.2 mmole) of 2-(3-chloropro pylamino)-5-chlorobenzophenone, 3O mmole of potassium iodide and an excess of ammonia in 25 ml. of ethanol was shaken at 100 in a sealed container for 4 hours. The reaction mixture was filtered and the filtrate reduced to dryness in vacuo. The residue was partitioned between 3 N sodium hydroxide and methylene chloride. The methylene chloride layer was washed with water, dried over anhydrous sodium sulfate and evaporated in vacuo to dryness. The residue was dissolved in benzene and chromatographed on a column of alumina (Woelm neutral, activity 1). After passing benzene through the column, elution with 1% ethanol in benzene gave a fraction which upon evaporation yielded 2-(3aminopropylamino)-5-chlorobenzophenone as an oil. Adding the oil to an excess of a solution of dry hydrogen chloride in ether gave 2 (3-aminopropylamino)-5-chlorobenzophenone hydrochloride which after recrystallization from isopropanol-ether was obtained as yellow needles of melting point Example 25 A mixture of 5.0 g. (16 mmole) of 2-(3-chloropropylamino)-5-chlorobenzophenone, 16 mmole of potassium iodide and an excess of methylamine in ethanol was agitated at 100119 for 4 /2 hrs. in a sealed container. The reaction mixture was poured into 800 ml. of water containing a small amount of sodium hydroxide and extracted with methylene chloride. The methylene chloride extract was washed with water, dried over anhydrous sodium sulfate and the solvent removed leaving an oil. The oil was warmed in 3 N HCl and the so-warmed medium neutralized with sodium hydroxide. Extraction with methylene chloride and removal of the solvent gave a yellow oil which when treated with hydrogen chloride in ether gave 5-chloro-2-(3-methylaminopropylamino)- benzophenone hydrochloride, melting point 200-205.

Example 26 A mixture of 5.4 g. (17.5 mmole) of 2-(3-chloropropylamino)-5-chlorobenzophenone, 20 mmole of potassium iodide and 25 ml. (excess) of piperidine was refluxed overnight. The reaction mixture was filtered and the piperidine removed from the filtrate in vacuo. The residue was dissolved in methylene chloride and the resultant solution washed with 1 N sodium hydroxide and then with water. The solvent was removed in vacuo leaving 5-chloro-2-(3-piperidinopropylamino)benzophenone as a yellow oil. 5-ch1oro-2-(3-piperidinopropylamino)benzophenone hydrochloride was obtained by adding the oil to methanolic hydrogen chloride. Upon recrystallization A solution of 16.7 g. (49.8 mmole) of -chloro-2-(3- dimethylaminopropylamino) 2-fluorobenzophenone, 85 g. of hydroxylamine hydrochloride and 200 ml. of pyridine was refluxed for 24 hours. An additional g. of hydroxylamine hydrochloride was added and the refluxing was continued for a total of 96 hours. The reaction mixture was poured into an iced excess of 3 N sodium hydroxide. Extraction of the so-cooled reaction mixture with methylene chloride, washing with water and removal of the solvent gave a solid. Crystallization of the solid from other and subsequent recrystallization from ethanol gave colorless needles of 2-(3-dimethylaminopropylamino)-S-chloro-2-fluorobenzophenone oxime, melting point 170-171.

Example 28 A mixture of 34.5 g. (0.103 mole) of 5-chl0ro-2-(3- dimethylaminopropylamino)-2-fluorobenzophenone, 1.0 g. of zinc chloride and an excess of methylamine in 250 ml. of ethanol was sealed in a bomb under 1000 psi. of nitrogen and shaken at 150 for about 3 hours. The reaction mixture was filtered and the filtrate reduced in vacuo to give a mixture of two isomeric 5-chloro-2-(3- dimethylaminopropylamino) 2 methylamino benzophenone methylimines as yellow prisms, melting point 90103.

If desired, the isomers could be separated. Fractional recrystallization from hexane gave isomer 21" melting at 109-111 and concentrate of the mother liquors gave isomer b melting at 110-113.

Example 29 5.0 g. of 5-chloro-2-(3-dimethylarninopropylamino)-2'- methylarnino benzophenone methylimine was dissolved in 50 ml. of ethanol and 100 ml. of 3 N hydrochloric acid. The solution was heated at reflux for 3% hours, neutralized and extracted with methylene chloride and gave after drying and removal of the solvent in vacuo an orange oil. Crystallization from hexane-petrol gave S-chloro 2 (3 dimethylaminopropylamino)-2'-methylaminobenzophenone of yellow prisms, melting point 85-87".

Example 30 A mixture of 13.0 g. of 7-chloro-2,3-dihydro-5-phenyl- 1H-1,4-benzodiazepine and 100 ml. of ethyl iodide was refluxed on a steam bath for one hour. The so-refluxed mixture was evaporated to dryness in vacuo. The residue was dissolved in a small amount of methanol and the resulting solution added to one and one-half liters of water. The pH of the resulting medium was adjusted to 7-8 with ammonium hydroxide. Tars were removed by filtration through cotton. The aqueous solution was washed with ether and evaporated to dryness in vacuo. Isopropanol was added to the residue and 7-chloro-2,3-dihydro-4-ethyl- S-phenyl-lI-I-1,4-benzodiazepin-4-ium iodide separated as yellow crystals melting at 208212. Recrystallization from a methanolether mixture gave the product as yellow prisms melting at 210-212.

A mixture of 2.8 g. (6.8 mmole) of 7-chloro-2,3-dihydro-4-ethyl-5-phenyl-1H-1,4-benzodiazepin-4-ium iodide in 300 ml. of water and 50 ml. of ethanol was stirred at room temperature. An equimolar amount of l N sodium hydroxide solution was carefully added to the sostirred mixture. The reaction mixture was diluted with an additional 100 ml. of water and extracted with ether. The ether extract was washed three times with water and once with brine. The so-washed ether extract was dried over sodium sulfate and reduced in vacuo to a yellow oil. The oil was crystallized from petroleum ether. Upon recrystallization from petroleum ether 7-chloro-2-(Z-ethylamino 18 ethylamino)-benzophenone was obtained as yellow rods, melting at 6466.

Example 31 A mixture of 32.0 g. of 7-chloro-2,3-dihydro-5-(2- fiuorophenyl)-1H-1,4-benzodiazepine and 260 ml. of ethyl iodide was refluxed on a steam bath for two hours. The excess ethyl iodide was removed in vacuo. The residue remaining after removal of the excess iodide was dis solved in warm isopropanol, ether was added, and 7-chloro 2,3 dihydro 4 ethyl-5-(2-fiuorophenyl)-1H- 1,4-benzodiazepin-4-ium iodide as a red crystalline precipitate appeared melting at 242245. Recrystallization from methylene chloride-isopropanol-ether gave the quaternary iodide as orange rods melting at 244-247.

A solution of 15.0 g. (34.8 mmole) of 7-chloro-2,3- dihydro 4 ethyl-5-(2-fiuorophenyl)-1H-1,4-benzodiazepin-4-ium iodide and 300 m1. methanol was stirred at room temperature. An equimolar amount of 1 N sodium hydroxide was carefully added to the so-stirred medium. The methanol was removed in vacuo and 200 ml. of water was added to dissolve the residual yellow oil. The aqueous solution was extracted several times with ether, and the combined ether extracts were washed twice with water, once with brine, dried over sodium sulfate, and reduced in vacuo to give 7-chloro-2-(Z-ethylaminoethylamino)-2'-fluorobenzophenone as a yellow oil. The oil was dissolved in a small amount of absolute ethanol. Upon addition of an excess of a solution of ethanolic hydrogen chloride to the so-formed medium 7-chloro-2- (Z-ethylaminoethylamino)-2-fiuorobenzophenone monohydrochloride precipitated as yellow crystals, melting at 205-215 Example 32 A tablet dosage form was prepared containing the following ingredients:

Ingredients per tablet- Mg.

5-chloro 2 (3 dimethylaminopropyl)amino- 2'-fluorobenzophenone hydrochloride 25 Lactose, spray dried 72 Corn starch, U.S.P. 2 Calcium stearate 1 Total weight The procedure for preparing the tablet dosage form was as follows:

In a suitable mixer, the 5-chloro-2-(3-dimethylaminopropyl)-amino-2-fluorobenzophenone hydrochloride, lactose, the corn starch and the calcium stearate were blended. The mixed powder was compressed on a heavy duty tablet compressing machine to yield tablet slugs of about 1" diameter and A" thickness. The tablet slugs were passed through a suitable comminu'ting machine to yield granules of approximately 16 mesh with a minimum of fines. The granulation was recompressed on a tablet compressing machine using a A" standard concave punch to an average tablet weight of 100 mg.

Example 33 A capsule dosage form containing the following ingredients was prepared as follows:

Ingredients per capsule- The procedure for preparing the capsule dosage form is as follows:

Mix the active component with the lactose and the corn starch in a suitable mixer. Further, blend the mixture by passing it through a Fitzpatrick Comminuting Machine with a No. 1A screen with knives forward. Return the blended powder to the mixer. Add the tale and blend thoroughly. Fill into No. 4 hard shell gelatin capsules on a capsulating machine.

Example 34 A suppository dosage form was prepared containing the following ingredients:

Per 1.3 gm.

Ingredient suppository chloro 2-(3-dimethylaminopropyl)amino- 2-fluorobenzophenone hydrochloride 0.010

Wecobee M 1.245

Carnauba wax 0.045

1 A refined synthetic cocoa butter, coconut derived.

The procedure for preparing the suppository dosage form was as follows:

The Wecobee M and the carnauba wax were melted in a suitable size glass lined container. The melt was mixed well and then cooled to 45. The 5-chloro-2-(3-dimethylaminopropyl)amino 2-fluorobenzophenone hydrochloride, which had been reduced to a fine powder with no lumps, was added to the so-cooled melt and stirred until completely and uniformly dispersed therein. The mixture was poured into suppository molds to yield suppository dosage forms having an individual Weight of 1.3 gms. The suppositories were cooled and removed from molds. They were then individually wrapped in wax paper for packaging.

Example 35 A dosage form of 5-chloro-2-(3-dimethylaminopropyl) amino-2-fluorobenzophenone hydrochloride suitable for parenteral use was prepared as follows:

50 mg. of parenteral grade 5-ehloro-2(3-dimethylaminopropyl)amino-2-fluorobenzophenone hydrochloride, fiber free, was filled into a 5 cc. ampul utilizing a Diehl Mater electric filler. The ampuls were sealed and sterilized at 255 F. for 2 hours.

Immediately before use, the powder is solubilized with 5 cc. of water for injection, U.S.P.

We claim:

1. A compound selected from the group consisting of compounds of the formula l N-CH CHaCHzN R lower alkyl F R2 B wherein A is selected from the group consisting of oxygen, NOH, NH and N-lower alkyl; B is selected from the group consisting of phenyl and R -phenyl wherein R is selected from the group consisting of hydrogen, halogen, trifiuoromethyl, nitro, lower alkyl and lower alkoxy, R is selected from the group consisting of hydrogen and lower alkyl, R and R are selected from the group consisting of hydrogen, halogen, lower alkyl, trifiuoromethyl, nitro, amino and lower alkoxy and R is selected from the group consisting of hydrogen, lower alkyl, and lower alkenyl and the acid addition salts thereof with pharmaceutically acceptable acids.

2. A compound selected from the group consisting of compounds of the formula wherein A is selected from the group consisting of oxygen, NOH, NH and N-lower alkyl; B is selected from the group consisting of phenyl and R -phenyl wherein R is selected from the group consisting of hydrogen, halogen, trifluoromethyl, nitro, lower alkyl and lower alkoxy; R is selected from the group consisting of hydrogen and lower alkyl, R and R are selected from the group consisting of hydrogen, halogen, lower alkyl, trifiuoromethyl, nitro, amino and lower alkoxy and R is selected from the group consisting of hydrogen, lower alkyl, and lower alkenyl and the acid addition salts thereof with pharmaceutically acceptable acids.

3. 5 halo 2-(3-diloweralkylaminopropyl)amino-2- fiuorobenzophenone.

4. 5 chloro 2 (3-dimethylaminopropyl)amino-2- fiuorobenzophenone.

5. 5 halo 2-(3-diloweralkylaminopropyl)aminobenzophenone.

6. 2 (3 diloweralkylaminopropyl)amino-S-nitrobenzophenone.

References Cited UNITED STATES PATENTS 3,131,178 4/1964 Archer et a1 26057O XR 3,136,815 6/1964 Reeder et a1. 260-570 XR 3,141,890 7/1964 Reeder et a1 260570 XR 3,182,054 5/1965 Sternbach et al. 260-566 XR 3,203,990 8/1965 Keller et a1 260566 XR 3,222,359 12/1965 Reeder et al. 260566 XR 3,239,564 3/1966 Reeder et a1. 260-566 XR CHARLES B. PARKER, Primary Examiner.

R. V. HINES, Assistant Examiner.

US. Cl. X.R. 

